Levetiracetam antiepilepticefficacy increasing using recombinant inter leukin-1 receptors antagonist in conditions of experimental chronic convulsive syndrome


  • R. S. Vastyanov
  • Yu. S. Strelnikova
Keywords: recombinant interleukin-1 receptors antagonist, levetіracetam, kindling, postkindling, chronic convulsive syndrome

Abstract

The data of experimental trials are given showing the peculiarities of the levetiracetam (LEV) anticonvulsive efficacy on the background of interleukin receptor blockade in conditions of chronic seizure syndrome different models. LEV and recombinant antagonist of interleukin-1-beta (RAIL) co-administration were shown to enhance the LEV anticonvulsive activity in kindled condition. The compound in such conditions also realizes its activity in postkindling model. The authors concluded the oppression of chronic seizures with interleukin receptor blockade, as well as development on this background, a more pronounced anticonvulsant effectiveness of LEV. Authors concluded about the chronic convulsive syndrome suppression in conditions of interleukin receptor blockade as well as more pronounced LEV anticonvulsant efficacy development on this background.

Published
2017-03-31
How to Cite
Vastyanov, R. S., & Strelnikova, Y. S. (2017). Levetiracetam antiepilepticefficacy increasing using recombinant inter leukin-1 receptors antagonist in conditions of experimental chronic convulsive syndrome. Biomedical and Biosocial Anthropology, (26), 65-68. Retrieved from https://bba-journal.com/index.php/journal/article/view/132